FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1126-1128 April 25, 1996 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Over a century ago, the German pathologist Rudolf Virchow presented a hypothesis that three factors — vessel injury, altered blood flow, and changes in blood coagulability — were responsible for vascular thrombosis. This concept, now immortalized as "Virchow's triad," has become the central paradigm to explain venous and arterial thromboembolism. Venous thrombi contain few platelets, abundant fibrin, and many trapped red cells; they are produced by the activation of the plasma coagulation system and form in areas of stasis. They are effectively treated with anticoagulants such as heparin that retard the generation of thrombin and the formation of fibrin. In . . . [Full Text of this Article]

References

Related Letters:

Aspirin and Coronary Disease
Vogel R. A., Handin R. I.
Extract | Full Text  
N Engl J Med 1996; 335:1161-1162, Oct 10, 1996. Correspondence

This article has been cited by other articles:

• Liu, M., Wallmon, A., Olsson-Mortlock, C., Wallin, R., Saldeen, T. (2003). Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am. J. Clin. Nutr. 77: 700-706 [Abstract] [Full Text]  
• Barakat, K., Kennon, S., Hitman, G. A., Aganna, E., Price, C. P., Mills, P. G., Ranjadayalan, K., North, B., Clarke, H., Timmis, A. D. (2001). Interaction between smoking and the glycoprotein IIIa P1A2 polymorphism in Non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 38: 1639-1643 [Abstract] [Full Text]  
• Bennett, J. S., Catella-Lawson, F., Rut, A. R., Vilaire, G., Qi, W., Kapoor, S. C., Murphy, S., FitzGerald, G. A. (2001). Effect of the PlA2 alloantigen on the function of {beta}3-integrins in platelets. Blood 97: 3093-3099 [Abstract] [Full Text]  
• Kastrati, A., Koch, W., Gawaz, M., Mehilli, J., Bottiger, C., Schomig, K., von Beckerath, N., Schomig, A. (2000). PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J Am Coll Cardiol 36: 84-89 [Abstract] [Full Text]  
• Hauser, W., Knobeloch, K.-P., Eigenthaler, M., Gambaryan, S., Krenn, V., Geiger, J., Glazova, M., Rohde, E., Horak, I., Walter, U., Zimmer, M. (1999). Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc. Natl. Acad. Sci. USA 96: 8120-8125 [Abstract] [Full Text]  
• Kastrati, A., Schomig, A., Seyfarth, M., Koch, W., Elezi, S., Bottiger, C., Mehilli, J., Schomig, K., von Beckerath, N. (1999). PlA Polymorphism of Platelet Glycoprotein IIIa and Risk of Restenosis After Coronary Stent Placement. Circulation 99: 1005-1010 [Abstract] [Full Text]  
• Geppert, A., Graf, S., Beckmann, R., Hornykewycz, S., Schuster, E., Binder, B. R., Huber, K. (1998). Concentration of Endogenous tPA Antigen in Coronary Artery Disease : Relation to Thrombotic Events, Aspirin Treatment, Hyperlipidemia, and Multivessel Disease. Arterioscler. Thromb. Vasc. Bio. 18: 1634-1642 [Abstract] [Full Text]  
• Altman, R. (1998). Controversies in Antithrombotic Therapy in Cardiovascular Diseases. CLIN APPL THROMB HEMOST 4: 11-24 [Abstract]  
• Vogel, R. A., Handin, R. I. (1996). Aspirin and Coronary Disease. NEJM 335: 1161-1162 [Full Text]